Bill Text: NH SB355 | 2024 | Regular Session | Amended
Bill Title: Relative to newborn screening for cytomegalovirus.
Spectrum: Partisan Bill (Republican 4-0)
Status: (Passed) 2024-07-30 - Signed by the Governor on 07/26/2024; Chapter 0282; Effective 01/01/2025 [SB355 Detail]
Download: New_Hampshire-2024-SB355-Amended.html
SB 355-FN - AS AMENDED BY THE SENATE
02/15/2024 0565s
2024 SESSION
24-2852
05/06
SENATE BILL 355-FN
AN ACT relative to newborn screening for cytomegalovirus.
SPONSORS: Sen. Innis, Dist 7; Sen. Birdsell, Dist 19; Sen. Ward, Dist 8; Sen. Carson, Dist 14
COMMITTEE: Health and Human Services
-----------------------------------------------------------------
AMENDED ANALYSIS
This bill directs the department of health and human services to provide information on the importance of early detection of cytomegalovirus (CMV) through the New Hampshire newborn screening program, established in RSA 132:10-a and to provide an update on targeted newborn CMV screening to the oversight committee on health and human services.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
02/15/2024 0565s 24-2852
05/06
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty Four
AN ACT relative to newborn screening for cytomegalovirus.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 Department of Health and Human Services; Early Detection of Cytomegalovirus. The department of health and human services shall provide information on the importance of early detection of cytomegalovirus (CMV) through the New Hampshire newborn screening program, established in RSA 132:10-a, and include an update on targeted newborn CMV screening in New Hampshire to the oversight committee on health and human services, established in RSA 126-A:13, for inclusion in the department’s annual report, pursuant to RSA 132:10-a, IV, on or before March 1, 2025.
2 Effective Date. This act shall take effect upon its passage.
24-2852
Revised 1/22/24
SB 355-FN- FISCAL NOTE
AS INTRODUCED
AN ACT relative to newborn screening for cytomegalovirus.
FISCAL IMPACT: [ X ] State [ ] County [ ] Local [ ] None
|
| |||||
Estimated State Impact - Increase / (Decrease) | ||||||
| FY 2024 | FY 2025 | FY 2026 | FY 2027 | ||
Revenue | $0 | $0 | $537,500+ | $537,500+ | ||
Revenue Fund(s) | Fees deposited into the newborn screening fund; insurance premium tax revenue | |||||
Expenditures | $0 | $0 | $537,500 | $537,500 | ||
Funding Source(s) | Newborn screening fund | |||||
Appropriations | $0 | $0 | $0 | $0 | ||
Funding Source(s) | None | |||||
• Does this bill provide sufficient funding to cover estimated expenditures? [X] Yes • Does this bill authorize new positions to implement this bill? [X] No | ||||||
METHODOLOGY:
This bill requires newborn screenings for cytomegalovirus (CMV), and requires the Department of Health and Human Services to establish fees to be paid by hospitals to cover costs associated with an ultrasound or amniocentesis if certain clinical symptoms are present. As with certain existing fees, the fees will be deposited into the newborn screening fund, which is used to cover laboratory analysis and other related costs. The Department notes that the newborn screening program currently screens for 37 heritable diseases at a cost of $146 per infant paid directly by birth hospitals. Based on data from Minnesota, the first state to implement universal CMV screening using blood spot, the Department estimates an additional cost of $43 per infant will be needed to implement the bill. Assuming 12,500 screenings annually, this will result in $537,500 in fees collected each year.
In addition, the Department states that, as with any newborn screen added to the existing panel, it will need to: collect and present information on CMV to the newborn screening advisory committee; work with the contracted laboratory to establish testing capabilities, protocols, and policies; develop metrics for tracking, screening, and confirmation of CMS; and produce and distribute educational materials. The Department assumes it will need a 0.5 full-time equivalent Program Specialist IV position at a cost of $58,000 (including equipment costs) in FY26 and $53,000 in FY27.
Although the Department does not explictly make this assumption, this fiscal note assumes that all revenues collected will be paid out by the Department to cover testing costs and the newly-established position, and hence expenditures will equal revenue collected.
The Department of Insurance states that, to the extent there is an increase in insurance claims for amniocentesis procedures, the bill may result in upward pressure on premium costs, potentially increasing insurance premium tax revenues.
As the bill has an effective date of July 1, 2025, it is assumed there will be no fiscal impact until FY26.
AGENCIES CONTACTED:
Departments of Insurance and Health and Human Services
